Insulin lingual - Flemington/Valentis
Latest Information Update: 03 Apr 2002
At a glance
- Originator NovaDel Pharma; Valentis
- Class
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 1 diabetes mellitus
Most Recent Events
- 03 Apr 2002 Discontinued - Preclinical for Type-1 diabetes mellitus in USA (Buccal)
- 03 Oct 2000 New profile
- 03 Oct 2000 Preclinical development for Type-1 diabetes mellitus in USA (Buccal)